Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
赤字転落
同社の業績は赤字に転じ、最新の年間損失はUSD です。
高配当
同社は高配当銘柄であり、最新の配当性向は287.84%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は287.84%です。
適正水準
同社の最新のPEは40.98で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は85.31M株で、前四半期比で8.71%減少しています。